| 51 |
34660618 | Case Report: Two Rare Cases of Complete Metabolic Response to Crizotinib in Patients With Rearranged ROS1 and ALK Metastatic Non-small Lung Cancer. | 2021 |
4 |
| 52 |
34686712 | Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement. | 2021 Oct 22 |
2 |
| 53 |
34715804 | Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada. | 2021 Oct 29 |
3 |
| 54 |
31509456 | Correlation of ROS1 Immunohistochemistry With ROS1 Fusion Status Determined by Fluorescence In Situ Hybridization. | 2020 Jun |
2 |
| 55 |
31607443 | ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS). | 2020 Jan |
1 |
| 56 |
31778074 | Dose-escalation trial of the ALK, MET & ROS1 inhibitor, crizotinib, in patients with advanced cancer. | 2020 Jan |
1 |
| 57 |
32143435 | Reactive Oxygen Species (ROS)-Sensitive Prodrugs of the Tyrosine Kinase Inhibitor Crizotinib. | 2020 Mar 4 |
1 |
| 58 |
32158297 | Incidence of ROS1-Rearranged Non-Small-Cell Lung Carcinoma in India and Efficacy of Crizotinib in Lung Adenocarcinoma Patients. | 2020 |
2 |
| 59 |
32167664 | First-line crizotinib versus platinum-pemetrexed chemotherapy in patients with advanced ROS1-rearranged non-small-cell lung cancer. | 2020 May |
4 |
| 60 |
32168429 | Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants. | 2020 May |
3 |
| 61 |
32208297 | A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab. | 2020 May |
1 |
| 62 |
32232958 | Effect of the patient information brochure in communicating the risks associated with crizotinib treatment to patients with non-small cell lung cancer (NSCLC) in Europe. | 2020 Apr |
1 |
| 63 |
32238411 | Crizotinib in ROS1 and MET Deregulated NSCLC-Letter. | 2020 Apr 1 |
1 |
| 64 |
32238412 | Crizotinib in ROS1 and MET Deregulated NSCLC-Response. | 2020 Apr 1 |
1 |
| 65 |
32269053 | Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer. | 2020 Jul 1 |
2 |
| 66 |
32409267 | Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non-small-cell Lung Cancer Progressing on Crizotinib. | 2020 Sep |
4 |
| 67 |
32433811 | A case of ROS1-rearranged lung adenocarcinoma exhibiting pleural effusion caused by crizotinib. | 2020 Jul |
2 |
| 68 |
32462394 | Clinical activity of brigatinib in ROS1-rearranged non-small cell lung cancer. | 2020 Dec |
1 |
| 69 |
32577365 | A case of ROS1-rearranged lung adenocarcinoma with osteoblastic bone metastasis. | 2020 |
1 |
| 70 |
32590748 | A novel TJP1-ROS1 fusion in malignant peripheral nerve sheath tumor responding to crizotinib: A case report. | 2020 Jun 26 |
1 |
| 71 |
32591465 | U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors. | 2020 Sep 15 |
2 |
| 72 |
32648475 | Matching-adjusted indirect comparison: entrectinib versus crizotinib in ROS1 fusion-positive non-small cell lung cancer. | 2020 Aug |
1 |
| 73 |
32652753 | Successful Treatment of Patients with Refractory High-Grade Serous Ovarian Cancer with GOPC-ROS1 Fusion Using Crizotinib: A Case Report. | 2020 Nov |
3 |
| 74 |
32702569 | Effectiveness and prognostic factors of first-line crizotinib treatment in patients with ROS1-rearranged non-small cell lung cancer: A multicenter retrospective study. | 2020 Sep |
6 |
| 75 |
32776005 | Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond? | 2020 Jun |
2 |
| 76 |
32792859 | Chidamide increases the sensitivity of Non-small Cell Lung Cancer to Crizotinib by decreasing c-MET mRNA methylation. | 2020 |
1 |
| 77 |
32865687 | Efficacy and Safety of Crizotinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with ROS1 Rearrangement or MET Alteration: A Systematic Review and Meta-Analysis. | 2020 Oct |
5 |
| 78 |
32871626 | Molecular and clinicopathological characteristics of ROS1-rearranged non-small-cell lung cancers identified by next-generation sequencing. | 2020 Nov |
3 |
| 79 |
32882995 | Novel Multitarget Therapies for Lung Cancer and Respiratory Disease. | 2020 Sep 1 |
1 |
| 80 |
33116618 | Identification of a Novel MPRIP-ROS1 Fusion and Clinical Efficacy of Crizotinib in an Advanced Lung Adenocarcinoma Patient: A Case Report. | 2020 |
6 |
| 81 |
33172113 | Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies. | 2020 Nov 6 |
5 |
| 82 |
33204104 | A Novel ROS1-FBXL17 Fusion Co-Existing with CD74-ROS1 Fusion May Improve Sensitivity to Crizotinib and Prolong Progression-Free Survival of Patients with Lung Adenocarcinoma. | 2020 |
10 |
| 83 |
33324391 | ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1-SHP2 Signaling Pathway in Non-Small Cell Lung Cancer. | 2020 |
1 |
| 84 |
33489827 | How selecting best upfront therapy for metastatic disease?-Focus on ROS1-rearranged disease. | 2020 Dec |
2 |
| 85 |
30350109 | Identification of a novel KLC1-ROS1 fusion in a case of pediatric low-grade localized glioma. | 2019 Jan |
1 |
| 86 |
30626830 | Successful Treatment of ROS1-rearranged Lung Cancer Complicated by Hypertrophic Pulmonary Osteoarthropathy with Crizotinib Therapy. | 2019 May 15 |
2 |
| 87 |
30642440 | Case report: Crizotinib is effective in a patient with ROS1-rearranged pulmonary inflammatory myofibroblastic tumor. | 2019 Feb |
1 |
| 88 |
30642448 | Exploration of germline variants responsible for adverse events of crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer by target-gene panel sequencing. | 2019 Feb |
1 |
| 89 |
30664990 | Molecular Analysis of Plasma From Patients With ROS1-Positive NSCLC. | 2019 May |
4 |
| 90 |
30719217 | ROS1-GOPC/FIG: a novel gene fusion in hepatic angiosarcoma. | 2019 Jan 4 |
2 |
| 91 |
30797499 | Identification of a novel WNK1-ROS1 fusion in a lung adenocarcinoma sensitive to crizotinib. | 2019 Mar |
4 |
| 92 |
30867785 | Clinicopathological features and clinical efficacy of crizotinib in Chinese patients with ROS1-positive non-small cell lung cancer. | 2019 Mar |
3 |
| 93 |
30915158 | ROS1 mutation non-small cell lung cancer-access to optimal treatment and outcomes. | 2019 |
2 |
| 94 |
30940295 | Different Types of ROS1 Fusion Partners Yield Comparable Efficacy to Crizotinib. | 2019 Aug 8 |
3 |
| 95 |
30976989 | Crizotinib in Chinese Patients with ROS1-Rearranged Advanced Non‒Small-Cell Lung Cancer in Routine Clinical Practice. | 2019 Jun |
4 |
| 96 |
30978502 | Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. | 2019 Jul |
1 |
| 97 |
30980071 | Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. | 2019 Jul 1 |
2 |
| 98 |
31027745 | Next-Generation Sequencer Analysis of Pulmonary Pleomorphic Carcinoma With a CD74-ROS1 Fusion Successfully Treated With Crizotinib. | 2019 May |
1 |
| 99 |
31085007 | Histopathologic characteristics of advanced-stage ROS1-rearranged non-small cell lung cancers. | 2019 Jul |
1 |
| 100 |
31118681 | High feasibility of cytological specimens for detection of ROS1 fusion by reverse transcriptase PCR in Chinese patients with advanced non-small-cell lung cancer. | 2019 |
1 |